KR20240060874A - 타크롤리무스를 포함하는 약제학적 제형, 이의 제조 방법 및 용도 - Google Patents

타크롤리무스를 포함하는 약제학적 제형, 이의 제조 방법 및 용도 Download PDF

Info

Publication number
KR20240060874A
KR20240060874A KR1020247014208A KR20247014208A KR20240060874A KR 20240060874 A KR20240060874 A KR 20240060874A KR 1020247014208 A KR1020247014208 A KR 1020247014208A KR 20247014208 A KR20247014208 A KR 20247014208A KR 20240060874 A KR20240060874 A KR 20240060874A
Authority
KR
South Korea
Prior art keywords
microparticles
polymer
poly
pharmaceutical formulation
stirring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247014208A
Other languages
English (en)
Korean (ko)
Inventor
에반겔로스 카라바스
에프티미오스 코우트리스
리다 칼란치
소티리아 차이티두
니코스 레모나키스
안나 파파다키
빈센트 브리유데즈
아르테미스 칼레지
아타나시오스 카세니스
카테리나 코티
Original Assignee
파마덴 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GR20210100639A external-priority patent/GR1010308B/el
Priority claimed from GB2116138.5A external-priority patent/GB2612779A/en
Application filed by 파마덴 에스.에이. filed Critical 파마덴 에스.에이.
Publication of KR20240060874A publication Critical patent/KR20240060874A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247014208A 2021-09-27 2022-09-27 타크롤리무스를 포함하는 약제학적 제형, 이의 제조 방법 및 용도 Pending KR20240060874A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GR20210100639A GR1010308B (el) 2021-09-27 2021-09-27 Φαρμακευτικο σκευασμα που περιλαμβανει τακρολιμους, μεθοδος για την παρασκευη και χρηση αυτου
GR20210100639 2021-09-27
GB2116138.5A GB2612779A (en) 2021-11-10 2021-11-10 Pharmaceutical formulation comprising Tacrolimus, method for the preparation thereof and use
GB2116138.5 2021-11-10
PCT/EP2022/025445 WO2023046321A1 (en) 2021-09-27 2022-09-27 Pharmaceutical formulation comprising tacrolimus, method for the preparation thereof and use

Publications (1)

Publication Number Publication Date
KR20240060874A true KR20240060874A (ko) 2024-05-08

Family

ID=83902713

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247014208A Pending KR20240060874A (ko) 2021-09-27 2022-09-27 타크롤리무스를 포함하는 약제학적 제형, 이의 제조 방법 및 용도

Country Status (10)

Country Link
US (1) US20250319028A1 (https=)
EP (1) EP4440550A1 (https=)
JP (1) JP2024536879A (https=)
KR (1) KR20240060874A (https=)
AU (1) AU2022351126A1 (https=)
CA (1) CA3233139A1 (https=)
CO (1) CO2024005380A2 (https=)
MX (1) MX2024003886A (https=)
WO (1) WO2023046321A1 (https=)
ZA (1) ZA202403104B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120000593B (zh) * 2024-12-27 2026-03-20 广东药科大学 一种他克莫司微晶及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002365A2 (en) 2004-06-24 2006-01-05 Angiotech International Ag Microparticles with high loadings of a bioactive agent
MX2007011494A (es) 2005-03-17 2007-12-06 Elan Pharma Int Ltd Composiciones inyectables de compuestos inmunosupresores nanoparticulados.
WO2017173534A1 (en) * 2016-04-05 2017-10-12 The Hospital For Sick Children System for delivery of fk506 for enhancing nerve regeneration

Also Published As

Publication number Publication date
CO2024005380A2 (es) 2024-05-30
MX2024003886A (es) 2024-07-10
WO2023046321A1 (en) 2023-03-30
WO2023046321A8 (en) 2024-05-30
AU2022351126A1 (en) 2024-05-09
EP4440550A1 (en) 2024-10-09
CA3233139A1 (en) 2023-03-30
JP2024536879A (ja) 2024-10-08
US20250319028A1 (en) 2025-10-16
ZA202403104B (en) 2025-01-29

Similar Documents

Publication Publication Date Title
EP2982367B1 (en) Pharmaceutical composition for parenteral administration, containing donepezil
RU2449785C2 (ru) Мицеллярная композиция амфифильного блок-сополимера, содержащая таксан, и способ ее получения
Wischke et al. Development of PLGA-based injectable delivery systems for hydrophobic fenretinide
KR20040030869A (ko) 안구주위 또는 결막하부 투여를 위한 안과용 데포 제제
KR20220112737A (ko) 리바스티그민을 포함하는 장기지속형 제제 및 이의 제조방법
JP2010510206A (ja) 優れた初期放出抑制特性を有する徐放性マイクロカプセルの製造方法及びこれにより製造されるマイクロカプセル
KR20130024986A (ko) 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
JP2016527308A (ja) エンテカビル微小球及びこれを含む非経口投与用医薬組成物
JP2024526279A5 (https=)
IL309789A (en) Semaglutide storage systems and their use
KR20100017904A (ko) 마이크로입자 중에 소마토스타틴 유도체를 포함하는 연장-방출 조성물
KR20200049948A (ko) 난용성 약물 서방출용 미립구의 제조방법
CN103893129B (zh) 帕潘立酮缓释微球及其注射剂和该缓释微球的制备方法
EP1679065A1 (en) Controlled release compositions for interferon based on PEGT/PBT block copolymers
KR20240060874A (ko) 타크롤리무스를 포함하는 약제학적 제형, 이의 제조 방법 및 용도
CN103948911A (zh) 一种棘白菌素类抗真菌药物缓释微球制剂及其制备方法
AU2007263004A1 (en) Sustained release formulations of aromatase inhibitors
CN118043036A (zh) 包含他克莫司的药物制剂、其制备方法和用途
GB2612779A (en) Pharmaceutical formulation comprising Tacrolimus, method for the preparation thereof and use
HK40104581A (zh) 包含他克莫司的药物制剂、其制备方法和用途
US20240216280A1 (en) Microsphere formulations comprising nalmefene andmethods for making and using the same
US20190117573A1 (en) Composition and method of preparation of risperidone extended release preparation
CN1969820A (zh) 抗癌药物组合物
KR20250094597A (ko) 약물의 특성에 따른 활성형 미립자의 제조 방법, 이의 제조 방법으로 제조된 활성형 미립자 및 상기 활성형 미립자를 이용한 약물을 포함하는 장기 지속 제형의 제조 방법
WO2025096848A1 (en) Ph-controlled biodegradable polymeric particles for sustained release of positively charged species

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000